The prevalence of uveitis and its associated complications is increasing globally, with the condition occurring in nearly 714 per 100,000 population and accounting for about 25% of all cases of blindness. Further, studies reveal that ongoing inflammation in untreated uveitis and complications linked to this uncontrolled inflammation are likely to be the reason behind 10% of the blindness in the United States. As a result, there is a growing interest in exploring effective treatment options that offer longer-lasting results and prevent vision loss in uveitis-affected patients.
The Uveitis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into uveitis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Uveitis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The uveitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from uveitis.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to uveitis.
Uveitis refers to an inflammatory disease that involves inflammation of the middle layer of the eye called uvea. The disease can be caused due to infections, idiopathic cases, trauma, and inflammatory diseases. The symptoms can range from redness, pain, and blurry vision to complete vision loss, indicating that prompt treatment is essential to prevent severe complications. Anterior uveitis ranks as the most prevalent type of the condition, comprising nearly 50% of all uveitis cases, whereas posterior uveitis is reported as the least common form.
Treatment for uveitis depends on the underlying cause of the disease. Symptom-based treatments typically focus on pain control, inflammation reduction (steroids and nonsteroidal anti-inflammatory drugs (NSAIDs)), and condition-specific treatments. There is an increased emphasis on developing biologic drugs that target specific inflammatory pathways and new classes of small-molecule inhibitors, such as JAK inhibitors, in order to expand treatment options. Further, the rising investment in ophthalmic drug development and advancements in drug delivery technologies are driving the uveitis drug pipeline forward with several highly promising candidates in clinical development.
This section of the report covers the analysis of uveitis drugs based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for uveitis. There are around 109 drugs in phase II for uveitis.
The drug molecule categories covered under uveitis pipeline analysis are corticosteroids, immunosuppressants/immunomodulators, biologic agents, anti-TNF agents, interleukin inhibitors, jak inhibitors, calcineurin inhibitors, anti-VEGF agents, antibiotics and antivirals, and small-molecule inhibitors. The choice of treatment depends on multiple factors including the underlying inflammation and the immune response involved in the condition.
The EMR report for the uveitis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in uveitis clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by Priovant Therapeutics, Inc., brepocitinib is a selective tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitor that is being investigated in a Phase 3 clinical trial with around 220 participants having active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
QLETLI (Adalimumab Injection), Bio-Thera's biosimilar to Humira® is undergoing a Phase 4 post-marketing clini...
Izokibep is in a Phase 2 study to evaluate its clinical activity against treating active non-infectious, inter...
Currently, in Phase 1 of a prospective, single-center phase 1 clinical study, Laquinimod eye drops are under i...
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
The Uveitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for uveitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within uveitis pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share